Category: Hypertension
Physicians in Europe have been slow to adopt renal denervation technology to treat high blood pressure, Medtronic CEO Omar Ishrak says, due to low reimbursement rates and a lack of understanding of the cutting-edge procedure.
Medtronic (NYSE:MDT) CEO Omar Ishrak said low reimbursement rates and a lack of understanding of the technology have hampered the uptake of renal denervation for high blood pressure in Europe.
Renal denervation devices have gotten a lot of attention for their potential to manage high blood pressure without drugs, but they may have the added side effect of lessening ventricular arrhythmias, researchers say.
Renal denervation technologies, which are already the focus of much clinical attention for the potential to treat high blood pressure without drugs, may have a bonus side-effect in keeping the heart in check, according to researchers.
ReCor Medical enrolls the 1st patients in a post-market study of its ultrasound-based renal denervation therapy in treatment of resistant high blood pressure.
California medical device startup ReCor Medical launched a post-market study of its next-generation Paradise renal denervation system in treatment of patients with resistant high blood pressure.
The 50-patient study has already enrolled patients at a participating facility in the Netherlands with the Paradise device, the only renal denervation device on the European market that treats high blood pressure with ultrasound rather than radiofrequency.
Medical device company St. Jude Medical launches a landmark study of its Enlightn renal denervation in order to find out whether the nerve ablating treatment has unexpected health benefits beyond lowering high blood pressure.
St. Jude Medical (NYSE:STJ) is aiming to take its renal denervation therapy a step further, looking for signs that the minimally invasive treatment improves health beyond lowering high blood pressure in patients with uncontrolled hypertension.
Medical device maker St. Jude Medical enrolls the 1st patient in a post-market study of its Enlightn renal denervation system, hoping to expand research to patients with less severe forms of hypertension.
Medtech giant St. Jude Medical (NYSE:STJ) launched a new trial of its Enlightn renal denervation system, hoping to demonstrate the value of the technology in a larger clutch of patients.
Medical device startup ReCor Medical wins CE Mark approval in the European Union for its 2nd-generation Paradise system, the only renal denervation device on the European market that treats high blood pressure with ultrasound rather than radiofrequency.
European regulators granted CE Mark approval to California-based medical device startup ReCor Medical for its 2nd-generation Paradise system, which treats drug-resistant hypertension by targeting the renal nerves.
Medical device maker launches commercial sales of its OneShot renal denervation system in Europe, Middle East, Africa, Asia and Latin America.
Medical device maker Covidien (NYSE:COV) this week announced commercial launch of its OneShot renal denervation system in markets around the world, bringing the company up to speed with some of its renal denervation rivals.
